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Abstract
Cannabis (known in its common forms as Cann bis sativa or Cannabis indica)
is the most widely used illicit drug in the world and has been used for thousands of
years for medicinal, religious and hedonistic purposes.  In the last half of the 20th
century the therapeutic uses of cannabis were largely ignored as most Western
governments prohibited the use of the drug.  Prohibition has come about largely as a
result of the view that cannabis is a dangerous drug that poses major risks to both
mental and physical health.  However, this view is being increasingly challenged in
recent years with a major popular movement towards decriminalization of cannabis
occurring in some Western countries and a resurgence of interest in the m dicinal
properties of cannabis.
Since Mechoulam and colleagues first isolated D 9-tetrahydrocannabinol (D 9-
THC) as the main psychoactive constituent of cannabis, considerable advances have
been made in the pharmacology of cannabis and cannabis-like drugs (cannabinoids).
Central and peripheral cannabinoid receptors have been isolated and two endogenous
ligands have been discovered.  In addition, two cannabinoid receptor antagonists have
been developed.  However, our knowledge of the behavioural, neural and emotional
effects of cannabis and the cannabinoids has often lagged behind our understanding of
basic cannabinoid pharmacology.
The present thesis attempts to further the understanding of the behavioural,
neural and emotional effects of cannabinoids, using laboratory rats as subjects.  A
synthetic analogue of D 9-THC (CP 55,940), is used as the primary pharmacological
tool.  The thesis offers a broad perspective with three major areas of investigation.
These are:  1) the effects of CP 55,940 on anxiety-related behaviour (Chapters 2 and
3);  2) the effects of CP 55,940 on patterns of brain activation as indicated by c-fos
expression (Chapter 4) and;  3) the addictive potential of CP 55,940 and its capacity to
produce sensitization to the effects of other drugs such as cocaine (Chapters 5 and 6).
A recurring theme throughout the thesis is that genetic factors may partially determine
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the behavioural, neural and emotional response to cannabinoids.  To this end, the
thesis compares Lewis and Wistar strains of rat in a wide variety of assays.  Previous
research as isolated Lewis rats as an “addiction-prone” and a “cannabinoid-
preferring” strain, as they are more sensitive to the rewarding effects of various drugs
of abuse including cannabinoids.  Conversely, cannabinoids appear to have aversive
effects in Wistar rats.
A long-standing puzzle in cannabinoid research has been the question of why
rats do not self-administer cannabis or cannabinoids.  One likely reason is that
cannabinoids have predominately aversive effects in rats.  It is proposed here that
these aversive effects arise because cannabinoids are anxiogenic agents in most rat
strains.  However some evidence indicates that the Lewis strain of rat are the only
strain to find cannabinoids rewarding.  It is hypothesised that Lewis rats may be more
susceptible to the rewarding effects of cannabinoids because they are less susceptible
to the anxiogenic effects of these compounds. 
In Chapters 2 and 3 the anxiogenic effects of the synthetic cannabinoid agonist
CP 55,940 were compared in Lewis and Wistar rats in several different animal models
of anxiety.  In Chapter 2, the predatory odour avoidance, open area avoidance and
conditioned ultrasonic vocalization (USV) models were utilised.  In the predatory
odour avoidance model, rats were exposed to cat odour in a rectangular arena and
given the opportunity to hide in a small box.  Both Lewis and Wistar rats displayed
high levels of hiding during odour exposure.  In Wistar but not Lewis rats, 50 µg/kg
of CP 55,940 (i.p.) enhanced this avoidance response.  Unfortunately, Lewis rats
showed exceptionally high avoidance of the cat odour making it difficult to discern the
effects of CP 55,940.  To avoid this problem a second experiment was conducted,
where rats were tested in the same arena as in the first experiment but with no cat
odour present.  Again in Wistar, but not Lewis rats, 25 and 50 µg/kg of CP 55,940
(i.p.) increased the avoidance of the open space.  In the third experiment, Lewis and
Wistar rats were placed in a chamber in which they had previously received
footshock.  Wistar but not Lewis rats re-exposed under the influence of 10, 25 or 50
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µg/kg CP 55,940 (i.p.) emitted significantly more USVs than vehicle-treated rats.
Thus, CP 55,940 clearly increased anxiety-related behaviour in Wistar rats but not
Lewis rats, supporting the notion of a genetic predisposition towards cannabinoid-
induced anxiety.  
In Chapter 3 the generality of the findings made in Chapter 2 were tested by
utilising two further animal models of anxiety, the social interaction and light-dark
emergence tests.  From the results of Chapter 2, it could be claimed that Lewis rats
were merely subsensitive to the effects of CP 55,940.  Therefore a higher dose range
(0, 25, 50 and 75 µg/kg i.p.) of CP 55,940 was employed in Chapter 3.  In addition,
the rotarod test was used to assess whether CP 55,940 has ataxic effects at hese
doses.  In the first experiment, two unfamiliar rats were placed in a large arena and the
time the rats spent socially interacting was recorded.  CP 55,940 significantly reduced
the total time rats spent socially interacting in Lewis (25 and 75 µg/kg) and Wistar rats
(50 and 75 µg/kg).  However, CP 55,940 has a significantly greater effect in Wistar
rats compared to Lewis rats.  In the second experiment, rats were placed in a small
box within a large open arena and the latency to emerge from this box was measured.
CP 55,940 increased emergence latency (at 75 µg/kg) and mean time per entry into the
box (at 25 and 75 µg/kg) in Wistar but not Lewis rats.  Furthermore, CP 55,940
caused a greater decrease in time spent in the open arena (at 25 and 75 µg/kg) and
frequency of emergence (at 75 µg/kg) in Wistar rats in comparison to Lewis rats.  In
the third experiment, CP 55,940 (at 25, 50 and 75 µg/kg) caused mild incoordination
only in Lewis rats as measured by the rotarod test.  This finding argues against the
assertion that the CP 55,940-induced anxiety-like behaviours in Wistar rats are merely
a result of motoric impairment.  Furthermore, it illustrates that Lewis ra s re not
generally subsensitive to the effects of CP 55,940.  That is, when compared to other
rat strains, Lewis rats may be more or less sensitive to the effects f CP 55,940
depending on what behaviour is being assessed.
From the results of Chapters 2 and 3 it can be seen that Lewis rats are less
sensitive to the anxiogenic effects of CP 55,940 than Wistar rats.  In Chapter 4 it was
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hypothesised that in Lewis rats the effects of CP 55,940 on neural substrates of reward
far outweigh the effects the compound has on neural substrates mediating anxiety.  To
examine this issue, the effects of CP 55,940 at a moderate (50 µg/kg i.p.) and high
(250 µg/kg i.p.) dose were observed on c-fos expression (a measure of neural
activation) and behaviour in Lewis and Wistar rats. CP 55,940 dose-dependently
inhibited locomotor activity and reduced body temperature with Lewis rats being
significantly less affected than Wistar rats.  The 250 µg/kg dose caused significant
catalepsy in both strains with a significantly greater effect in Wistar rats.  These strain
differences in the effects of CP 55,940 on body temperature and motor behaviour
clearly correlated with c-fosexpression in various regions and subregions.  In general,
Lewis rats showed significantly less Fos-labeled cells in comparison to Wistar rats.
These strain differences in the effects of CP 55,940 on c-fos expression appeared
unique to cannabinoids, as cocaine (15 mg/kg i.p.) had equivalent effects on c-fos
expression in Lewis and Wistar rats. 
CP 55,940 promoted c-fos expression in areas not previously assessed, such as
the median preoptic nucleus (MnPO), medial preoptic nucleus (MPO), anterior
hypothalamic area (AH), islands of Calleja (ICjM), periaqueductal gray (PAG) and the
pedunculopontine tegmental nucleus (PPTg). The strain differences uncovered in
Chapters 2 and 3 correlated well with strain differences in the effects of CP 55,940 on
c-fos expression in areas implicated in cannabinoid-induced anxiety, such as the central
nucleus of the amygdala, bed nucleus of the stria terminalis, paraventricular nucleus of
the hypothalamus and PAG.  However, the effects of CP 55,940 on c-fos expression in
a neural circuit which may underlie reward, which includes the shell of the nucleus
accumbens (NAS) and PPTg, were also less in Lewis rats in comparison to Wistar rats.
Future investigations must address whether the reduced effects of CP 55,940 on the
Lewis rat are due to pharmacokinetics or pharmacodynamics.  In addition, future
studies must reconcile the pattern of c-fos expression observed here with prior reports
of the Lewis rat being a unique “cannabinoid-preferring” strain.
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In Chapter 4, CP 55,940 administration promoted c-fos expression in areas of
the brain thought to play a critical role in behavioural sensitization such as the ventral
tegmental area and NAS.  This is interesting because it is possible that c-f  i  involved
in promoting neuroadaptations that underlie drug addiction.  To examine this idea,
Chapter 5 investigated a behavioural assay of the long-term neural adaptations that may
occur with the chronic administration of cannabis, namely, behavioural sensitization.
This chapter also examined an animal model of the “gateway hypothesis”, that is, the
hypothesis that prior exposure to cannabis increases a  individual’s vulnerability to
using other drugs.  This animal model is known as cross-sensitization.  First it was
shown that Lewis, but not Wistar rats, given cocaine (15 mg/kg i.p.) every second day
over a two week period displayed a progressively greater locomotor response to the
drug over days indicating behavioural sensitization.  When CP 55,940 (0, 10, 25 or 50
µg/kg i.p.) was administered under a similar regime, no such sensitization was
observed in either strain.  Rather, the two highest doses of CP 55,940 (25 and 50
µg/kg) caused locomotor suppression that lasted throughout administration.  When
Lewis or Wistar rats pre-exposed ten times to CP 55,940 were challenged with cocaine
(15 mg/kg), no exaggerated locomotor response to cocaine was evident relative to non
pre-exposed rats. When these rats were subsequently re-tested with CP 55,940, it
continued to produce a dose-dependent suppression of locom tor activity.  Finally,
when CP 55,940 (50 µg/kg) was co-administered with cocaine in Lewis rats, it
significantly reduced the locomotor hyperactivity produced by the drugbut did not
block the development of behavioural sensitization to cocaine.  These results show that
CP 55,940 does not sensitize locomotor activity with repeated administration i the
same way as cocaine, and that pre-exposure or concurrent exposure to CP 55,940 does
not enhance sensitivity to the subsequent behavioural effects of cocaine.  Therefore,
unlike Chapters 2, 3 and 4 where strain differences were observed in CP
55,940–induced anxiety, hypothermia, catalepsy, c-fos expression and ataxia, there
were no strain differences with respect to behavioural sensitization.
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Landmark studies by Gardner and colleagues howed that Lewis rats are
particularly susceptible, in comparison to other rat strains, to the rewarding effects of
D 9-THC on: 1) medial forebrain bundle (MFB) self-stimulation behaviour and; 2)
dopamine (DA) efflux in the NAS.  However, in Chapter 4 Lewis rats were less
susceptible than Wistar rats to CP 55,940-induced c-fos expression in the NAS.
Further, Lewis rats showed no behavioural sensitization to the chronic administration of
CP 55,940.  In light of these findings, Chapter 6 assessed whether CP 55,940 does
have a rewarding effect on MFB self-stimulation behaviour in Lewis rats.  Lewis rats
were trained to self-stimulate he MFB using a rate–frequency paradigm and then
administered CP 55,940 (0, 10, 25 and 50 µg/kg i.p.).  CP 55,940 had no effect on
MFB self-stimulation behaviour as assessed by the M50, the stimulation frequency at
which half-maximal response rates were obtained.  This result calls into question
previous assertions that Lewis rats are a “cannabis-preferring” strain of rat.
Previous studies utilising the cannabinoid CB1 receptor antagonist, SR 141716,
have shown that the endogenous cannabinoid system may have some involvement in
the rewarding effects of cocaine, morphine, sucrose and alcohol.  Thus, Chapter 6 also
assessed the effects of SR 141716 (0, 1, 3, 10 and 20 mg/kg i.p.) on MFB stimulation
in Lewis rats.  The role of DA in MFB stimulation reward has already been established,
so for comparison purposes the effects of the DA D1 receptor antagonist SCH 23390
(0.06 mg/kg i.p.) was also assessed.  Only a very high dose of SR 141716 (20 mg/kg)
caused a significant inhibition of the rewarding efficacy of the stimulation with all other
doses (1, 3, and 10 mg/kg) being ineffective in modulating the rewarding impact of
brain stimulation.  This was seen as an increase in M50.  By comparison, a relatively
low dose (0.06 mg/kg) of SCH 23390 caused a large increase in M50. These results
indicate a relatively modest influence of the endogenous cannabinoid system on reward-
relevant neurotransmission in the self-stimulation paradigm.
Chapter 7 concludes the thesis and discusses the implications of the results
obtained.  The main findings of the current thesis are: 1) that the suggested “addiction-
prone” Lewis strain of rat is less susceptible to cannabinoid-induced anxiety in
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comparison to Wistar rats; 2) Lewis rats show less cannabinoid-induced c-fos
expression in comparison to Wistar rats (including in brain regions implicated in
cannabinoid-induced anxiety and reward); 3) cannabinoid-induced c-fos expression
exists in a number of brain regions never previously assessed such as the MPO, ICjM
and PPTg; 4) behavioural sensitization does not occur with the repeated administration
of CP 55,940; 5) cannabinoid pre-exposure or co-administration does not increase the
sensitivity of the locomotor–activating effects of cocaine; 6) the endogenous
cannabinoid system, at most, only has a minor influence on the neural substrate of brain
stimulation reward and; 7) that there are previously unreported strain differences in
cannabinoid-induced hypothermia, catalepsy and ataxia.  These results add to our
understanding of the effects of the behavioural, emotional and neural effects of
cannabinoids and the endogenous cannabinoid system. 
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